Pharmidex are proud to be part of the recent publication on African Trypanosomiasis in Journal of Antimicrobial Agents

July 19, 2017

Pharmidex team are proud to present it's latest involvement on the recent publication on African Typanosomiasis

Pharmidex are proud to be part of the recent publication on African Trypanosomiasis in Journal of Antimicrobial Agents

The Pharmidex team are proud to present it's latest involvement on the recent publication on African Typanosomiasis which was published in the International journal of antimicrobial agents. Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis - International Journal of Antimicrobial Agents Human African trypanosomiasis (HAT) is a neglected tropical disease, with a population of 70 million at risk. Current treatment options are limited.

In the search for new therapeutics, the repurposing of the broad-spectrum antiprotozoal drug fexinidazole has completed Phase III trials with the anticipation that it will be the first oral treatment for HAT.

For more information please see - https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents

< Older Post

Newer Post >

BIA Annual Gala Dinner

January 29, 2026

Pharmidex is delighted to share that Ash Alavijeh , Head of Operations, will be attending the UK BioIndustry Association (BIA) Annual Gala Dinner at the Roundhouse, London. Ash is looking forward to connecting with pharma and biotech colleagues to explore new collaborations, partnerships, and opportunities, all with the shared goal of advancing drug discovery and development. If you’re attending, feel free to connect with Ash this evening.

Advanced Biomarker Analysis at Pharmidex

January 26, 2026

Pharmidex provides comprehensive biomarker and cytokine profiling services to support drug discovery and development across respiratory, autoimmune, metabolic and toxicology programmes. Using state-of-the-art bioanalytical platforms, we deliver robust, translational biomarker data to help understand mechanism of action, immune modulation and therapeutic efficacy. Let’s talk about how our biomarker expertise can strengthen your research. 🌐 https://www.pharmidex.com/BIOMARKERS_ANALYSIS

Pharmidex will be attending the BBMS Gala Dinner 2026

January 21, 2026

We’re delighted to share that Vasudha Tandon, PhD Principal Scientist at Pharmidex , will be attending the BBMS Gala Dinner 2026 on Thursday 22 January 2026 at the Old Hall, Queens’ College, Cambridge. This special evening, part of Building Bridges in Medical Sciences, brings together leaders from academia, industry, and healthcare to strengthen collaboration across the life sciences. Vasudha is looking forward to meeting fellow attendees and exploring new opportunities to build meaningful scientific partnerships.